2018

1) Felicetti T., Cannalire R., Pietrella D., Latacz G., Lubelska A., Manfroni G., Barreca M.L., Massari S., Tabarrin O., Kieć-Kononowicz K., Schindler B.D., Kaatz G.W., Cecchetti V., Sabatini S.: *2-Phenylquinoline S. aureus NorA efflux pump inhibitors: Evaluation of the importance of methoxy group introduction;* Journal of Medicinal Chemistry 2018, V.61, 17, 7827-7848, DOI: 10.1021/acs.jmedchem.8b00791

2) Łażewska D., Olejarz-Maciej A., Kaleta M., Bajda M., Siwek A., Karcz T., Doroz-Płonka A., Cichoń U., Kuder K., Kieć-Kononowicz K.: *4-tert-Pentylphenoxyalkyl derivatives - histamine H3 receptor ligands and monoamine oxidase B inhibitors*; Bioorganic & Medicinal Chemistry Letters 2018, V.28, 23-24, 3596-3600, DOI: 10.1016/j.bmcl.2018.10.048

3) Bastaki S.M., Abdulrazzaq Y.M., Shafiullah M., Więcek M., Kieć-Kononowicz K., Sadek B.: *Anticonvulsant and reproductive toxicological studies of the imidazole-based histamine H3R antagonist 2-18 in mice;* Drug Design, Development and Therapy 2018, V.12, 179194, DOI: 10.2147/DDDT.S144730

4) Alachkar A., Latacz G., Siwek A., Lubelska A., Honkisz E., Gryboś A., Łażewska D., Handzlik J., Stark H., Kieć-Kononowicz K., Sadek B.: *Anticonvulsant evaluation of novel non-imidazole histamine H3R antagonists in different convulsion models in rats;* Pharmacology, Biochemistry and Behavior 2018; V.170, 14-24, DOI: 10.1016/j.pbb.2018.04.010

5) Popiołek-Barczyk K., Łażewska D., Latacz G., Olejarz A., Makuch W., Stark H., Kieć-Kononowicz K., Mika J.: *Antinociceptive effects of novel histamine H_3R and H_4R receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse;* British Journal of Pharmacology 2018, V.175, 14, 2897-2910, DOI: 10.1111/bph.14185

6) Kucwaj-Brysz K., Kurczab R., Jastrzębska-Więsek M., Żesławska E., Satała G., Nitek W., Partyka A., Siwek A., Jankowska A., Wesołowska A., Kieć-Kononowicz K., Handzlik J.: *Computer-aided insights into receptor-ligand interaction for novel 5-*

arylhydantoin derivatives as serotonin 5-HT$_7$ receptor agents with antidepressant activity; European Journal of Medicinal Chemistry 2018, V.147, 102-114, DOI: 10.1016/j.ejmech.2018.01.093

7) Kurczab R., Ali W., Łażewska D., Kotańska M., Jastrzębska-Więsek M., Satała G., Więcek M., Lubelska A., Latacz G., Partyka A., Starek M., Dąbrowska M., Wesołowska A., Jacob C., Kieć-Kononowicz K., Handzlik J.: *Computer-aided studies for novel arylhydantoin 1,3,5-triazine derivatives as 5-HT$_6$ serotonin receptor ligands with antidepressive-like, anxiolytic and antiobesity action in vivo;* Molecules 2018, V.23, 10 2529, 1-26, DOI: 10.3390/molecules23102529

8) Kose M., Gollos S., Karcz T., Fiene A., Heisig F., Behrenswerth A., Kieć-Kononowicz K., Namasivayam V., Muller C.E.: *Fluorescent-labeled selective adenosine A2B receptor antagonist enables competition binding assay by flow cytometry*; Journal of Medicinal Chemistry 2018, V.61, 10, 4301-4316, DOI: 10.1021/acs.jmedchem.7b01627

9) Szczepańska K., Kuder K., Kieć-Kononowicz K.: *Histamine H3 receptor ligands in the group of (homo)piperazine derivatives;* Current Medicinal Chemistry 2018, V.25, 14, 1609 – 1626, DOI: 10.2174/0929867325666171123203550

10) Żesławska E., Nitek W., Tejchman W., Handzlik J.: *Influence of 3-5-[4-(diethylamino)benzylidene]rhodanine propionic acid on the conformation of 5-(4-chlorobenzylidene)-2-(4-methylpiperazin-1-yl)-3H-imidazol-4(5H)-one;* Acta Crystallographica. Section C, Structural Chemistry 2018, V.74, Pt 11, 1427-1433, DOI: 10.1107/S2053229618013980

11) Latacz G., Lubelska A., Jastrzębska-Więsek M., Partyka A., Kucwaj-Brysz K., Wesołowska A., Kieć-Kononowicz K., Handzlik J.: *MF-8, a novel promising arylpiperazine-hydantoin based 5-HT7 receptor antagonist : In vitro drug-likeness studies and in vivo pharmacological evaluation;* Bioorganic & Medicinal Chemistry Letters 2018, V.28, 5, 878-883, DOI: 10.1016/j.bmcl.2018.02.003

12) Reyes-Resina I., Navarro G., Aguinaga D., Canela E.I., Schoeder C.T., Załuski M., Kieć-Kononowicz K., Saura C.A., Muller C.E., Franco R.: *Molecular and functional interaction between GPR18 and cannabinoid CB_2 G-protein-coupled receptors. Relevance in neurodegenerative diseases;* Biochemical Pharmacology 2018, V.157, 169-179, DOI: 10.1016/j.bcp.2018.06.001

13) Więckowska A., Wichur T., Godyń J., Bucki A., Marcinkowska M., Siwek A., Więckowski K., Zaręba P., Knez D., Głuch-Lutwin M., Kazek G., Latacz G., Mika K., Kołaczkowski M., Korabecny J., Soukup O., Benkova M., Kieć-Kononowicz K., Gobec S., Malawska B.: *Novel multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease*; ACS Chemical Neuroscience 2018, V.9, 5, 1195-1214, DOI: 10.1021/acschemneuro.8b00024

14) Łażewska D., Kaleta M., Hagenow S., Mogilski Sz., Latacz G., Karcz T., Lubelska A., Honkisz E., Handzlik J., Reiner D., Satała G., Filipek B., Stark H., Kieć-Kononowicz K.: *Novel naphthyloxy derivatives potent histamine H_3 receptor ligands. Synthesis and pharmacological evaluation*; Bioorganic & Medicinal Chemistry 2018, V.26, 9, 2573-2585, DOI: 10.1016/j.bmc.2018.04.023

15) Szczepańska K., Karcz T., Kotańska M., Siwek A., Kuder K.J., Latacz G., Mogilski Sz., Hagenow S., Lubelska A., Sobolewski M., Stark H., Kieć-Kononowicz K.: *Optimization and preclinical evaluation of novel histamine H_3 receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives*; Bioorganic & Medicinal Chemistry 2018, V.26, 23-24, 6056-6066, DOI: 10.1016/j.bmc.2018.11.010

16) Koch P., Brunschweiger A., Namasivayam V., Ullrich S., Maruca A., Lazzaretto B., Kuppers P., Hinz S., Hockemeyer J., Wiese M., Heer J., Alcaro S., Kieć-Kononowicz Katarzyna, Muller Christa E.: *Probing substituents in the 1- and 3-position: tetrahydropyrazino-annelated water-soluble xanthine derivatives as multi-target drugs with potent adenosine receptor antagonistic activity*; Frontiers in Chemistry 2018, V.6, 26, 1-28, DOI: 10.3389/fchem.2018.00206

17) Łażewska D., Kieć-Kononowicz K.: *Progress in the development of histamine H_3 receptor antagonists/inverse agonists: a patent review (2013-2017)*; Expert Opinion on Therapeutic Patents 2018; V.28, 3, 175-196, DOI: 10.1080/13543776.2018.1424135

18) Dybas J., Grosicki M., Barańska M., Marzec K.M.: Raman imaging of heme metabolism *in situ* in macrophages and Kupffer cells; Analyst 2018, V.143, 14, 3489-3498, DOI: 10.1039/C8AN00282G

19) Tott Sz., Grosicki M., Klimas B., Augustyńska D., Chłopicki S., Barańska M.: *Raman spectroscopic features of primary cardiac microvascular endothelial cells (CMECs) isolated from the murine heart;* Analyst 2018, V.143, 24, 6079-6086, DOI: 10.1039/C8AN01308J

20) Latacz G., Hogendorf A.S., Hogendorf A., Lubelska A., Wierońska J.M., Woźniak M., Cieślik P., Kieć-Kononowicz K., Handzlik J., Bojarski A.J.: *Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists*; MedChemComm 2018, V.9, 11, 1882-1890, DOI: 10.1039/C8MD00313K

21) Alvarez-Perez M., Ali W., Marć M.A., Handzlik J., Domínguez-Alvarez E.: *Selenides and diselenides: A review of their anticancer and chemopreventive activity*; Molecules 2018, V.23, 3 628, 1-19, DOI: 10.3390/molecules23030628

22) Schoeder C.T., Kaleta M., Mahardhika A.B., Olejarz-Maciej A., Łażewska D., Kieć-Kononowicz K., Muller C.E.: *Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18*; European Journal of Medicinal Chemistry 2018, V.155, 381-397, DOI: 10.1016/j.ejmech.2018.05.050

23) Alachkar A., Łażewska D., Latacz G., Frank A., Siwek A., Lubelska A., Honkisz-Orzechowska E., Handzlik J., Stark H., Kieć-Kononowicz K., Sadek B.: *Studies on anticonvulsant effects of novel histamine H3R antagonists in electrically and*

chemically induced seizures in rats; International Journal of Molecular Sciences 2018, V.19, 11 3386, 1-23, DOI: 10.3390/ijms19113386

24) Jastrzębska-Więsek M., Siwek A., Partyka A., Kołaczkowski M., Walczak M., Smolik M., Latacz G., Kieć-Kononowicz K., Wesołowska A.: *Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats;* Naunyn-Schmiedeberg's Archives of Pharmacology 2018, V.391, 1, 37-49, DOI: 10.1007/s00210-017-1431-y

25) Szczepańska K., Karcz T., Mogilski Sz., Siwek A., Kuder K.J., Latacz G., Kubacka M., Hagenow S., Lubelska A., Olejarz A., Kotańska M., Sadek B., Stark H., Kieć-Kononowicz K.: *Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H_3R ligands*; European Journal of Medicinal Chemistry Szczegóły: 2018 : Vol. 152, s. 223-234, DOI: 10.1016/j.ejmech.2018.04.043

26) Ali W., Alvarez-Perez M., Marć M.A., Salardon-Jimenez N., Handzlik J., Dominguez-Alvarez E.: *The anticancer and chemopreventive activity of selenocyanate-containing compounds*; Current Pharmacology Reports 2018, V.4, 6, 468-481, DOI: 10.1007/s40495-018-0160-3

27) Kotańska M., Kuder K.J., Szczepańska K., Sapa J., Kieć-Kononowicz K.: *The histamine H_3 receptor inverse agonist pitolisant reduces body weight in obese mice*; Naunyn-Schmiedeberg's Archives of Pharmacology 2018, V.391, 8, 875-881, DOI: 10.1007/s00210-018-1516-2

28) Eissa N., Khan N., Ojha S.K., Łażewska D., Kieć-Kononowicz K., Sadek B.: *The histamine H3 receptor antagonist DL77 Ameliorates MK801-induced memory deficits in rats*; Frontiers in Neuroscience 2018, V.12, 42, 1-11, DOI: 10.3389/fnins.2018.00042

29) Eissa N., Jayaprakash P., Azimullah S., Ojha S.K., Al-Houqani M., Jalal F.Y., Łażewska D., Kieć-Kononowicz K., Sadek B.: *The histamine H3R antagonist DL77 attenuates*

autistic behaviors in a prenatal valproic acid-induced mouse model of autism; Scientific Reports 2018, V.8, 1, 13077, DOI: 10.1038/s41598-018-31385-7

30) Kucwaj-Brysz K., Kurczab R., Żesławska E., Lubelska A.M., Marć M.A., Latacz G., Satała G., Nitek W., Kieć-Kononowicz K., Handzlik J.: *The role of aryl-topology in balancing between selective and dual 5-HT$_7$R/5-HT$_{1A}$ actions of 3,5-substituted hydantoins*; MedChemComm 2018, V.9, 6, 1033-1044, DOI: 10.1039/C8MD00168E

31) Załuski M., Stanuch K., Karcz T., Hinz S., Latacz G., Szymańska E., Schabikowski J., Doroz-Płonka A., Handzlik J., Drabczyńska A., Muller C., Kieć-Kononowicz K.: *Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties*; MedChemComm 2018, V.9, 6, 951-962, DOI: 10.1039/C8MD00070K